Massachusetts General Hospital joins PanFAM-1 prospective study for the early detection of pancreatic cancer in familiar risk groups
Forming collaborations and establishing a presence in the USA is central to Immunovia’s reimbursement strategy and market introduction. The continued expansion of PanFAM-1 into the largest ever prospective multicenter study for early detection of pancreatic cancer is another vital step towards these goals. The participation of the prestigious MassGen will strengthen the study, which is designed to validate IMMrayTM PanCan-d, Immunovia´s blood-based test for early detection of pancreatic cancerLUND, Sweden, and Boston, USA ― Immunovia AB today announced that Massachusetts General Hospital